<DOC>
	<DOCNO>NCT01806792</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Risedronate , cholecalciferol combination tablet patient Osteoporosis</brief_summary>
	<brief_title>Post-menopausal Women Osteoporosis ( Phase III )</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety Monthly Risedronate cholecalciferol 25 Hydroxyvitamin D level bone marker patient osteoporosis .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1. woman osteoporosis 2. patient diagnosis Postmenopausal 6 Months bone mineral density Tscore &lt; 2.5 mean lumbar spine ( L14 ) , femoral neck , total , Tscore &lt; 1.0 radiologic evidence least one vertebral fracture . Menopause define natural menses least 1 year serum FSH level &gt; 40 IU/L , report hysterectomy 3. low level 25 ( OH ) D &gt; 9 ng/mL 4. patient give write consent agreement voluntarily participate clinical study 5. patient read understand write instruction 1. patient contraindication oral bisphosphonates , esophageal stricture 2 . ALT , AST ≥ 2×UNL Serum Creatinine ≥ 1.5×UNL 3. low level 25 ( OH ) D ( less 9 ng/mL ) . 4 . Previous use oral bisphosphonates vitamin D allow , washout period need , depend duration treatment . Twoyear washout period need bisphosphonate user 36month period require vitamin D user &gt; 200 IU . 5. drug administration diagnose alcoholic psychical disease 6. patient investigator judge improper participate clinical trial 7 ) 13.patients experience participate clinical trial within 30 day prior study participation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>